Latest news

• Standard steroid improves recovery of critically-ill COVID-19 patients

  The study evaluated hydrocortisone in 403 patients with suspected or confirmed COVID-19. ... with the steroid if their blood pressure dropped and a final group received no hydrocortisone.

• Diurnal files adrenal insufficiency drug Alkindi in US

  Diurnal said the US marketing application follows a meeting with the FDA which said it would be able to file Alkindi (hydrocortisone granules) under the regulatory pathway for generic drugs, which ... Care (IQWiG) concluded it had not been proven to be

• Resurgent Diurnal raises £5.4m for twin product filings

  The sustained-release formulation of hydrocortisone (the synthetic version of cortisol) is designed to mimic the circadian rhythm of cortisol when given in a twice-a-day ‘toothbrush’ regimen – once in ... IQWiG) concluded it had not been proven to

• MSD probed by UK for blocking Remicade biosimilars

  Last year it fined Pfizer £84m for conspiring with Flynn Pharma to raise the price of epilepsy drug phenytoin, and has since launched an investigation into the pricing of Actavis' hydrocortisone

• EU starts investigation of Aspen's cancer drug pricing

  launched an investigation into the pricing of Actavis' hydrocortisone tablets.